down arrow

Mersana Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US59045L1061
USD
27.47
-0.05 (-0.18%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Carisma Therapeutics, Inc.
Harpoon Therapeutics, Inc.
Stoke Therapeutics, Inc.
X4 Pharmaceuticals, Inc.
Mersana Therapeutics, Inc.
Selecta Biosciences, Inc.
Larimar Therapeutics, Inc.
Neoleukin Therapeutics, Inc.
Ikena Oncology, Inc.
InflaRx NV
Gritstone bio, Inc.
Why is Mersana Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate -0.32% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -62.93
2
Flat results in Jun 25
  • NET SALES(HY) At USD 5.81 MM has Grown at -49.64%
  • CASH AND EQV(HY) Lowest at USD 180.06 MM
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -45.19%, its profits have risen by 41.3%
4
Reducing Promoter Confidence
  • Promoters have decreased their stake in the company by -8.29% over the previous quarter and currently hold 25.62% of the company
  • Promoters decreasing their stake may signify reduced confidence in the future of the business
5
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -45.19% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Mersana Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Mersana Therapeutics, Inc.
-53.64%
0.53
2147.53%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
83.09%
EBIT Growth (5y)
-0.32%
EBIT to Interest (avg)
-62.93
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.53
Sales to Capital Employed (avg)
0.03
Tax Ratio
0.57%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.56
EV to EBIT
0.39
EV to EBITDA
0.40
EV to Capital Employed
0.28
EV to Sales
-0.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
70.43%
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -79.76 MM

NET PROFIT(HY)

Higher at USD -44.48 MM

ROCE(HY)

Highest at 0%

RAW MATERIAL COST(Y)

Fallen by -10.06% (YoY

NET SALES(Q)

At USD 3.06 MM has Grown at 33.28%

-5What is not working for the Company
NET SALES(HY)

At USD 5.81 MM has Grown at -49.64%

CASH AND EQV(HY)

Lowest at USD 180.06 MM

Here's what is working for Mersana Therapeutics, Inc.
Net Profit
Higher at USD -44.48 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Operating Cash Flow
Highest at USD -79.76 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
At USD 3.06 MM has Grown at 33.28%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Raw Material Cost
Fallen by -10.06% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Mersana Therapeutics, Inc.
Cash and Eqv
Lowest at USD 180.06 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."